"Designing Growth Strategies is in our DNA"

Asia Pacific Multiple Sclerosis Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Immunomodulators, Immunosuppressants, Interferons, and Others), By Route of Administration (Oral and Injection {Intramuscular, Subcutaneous, and Intravenous}), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2023-2030

Region : APAC | Format: PDF | Report ID: FBI107929



Play Audio Listen to Audio Version

Asia Pacific is the second largest region in the global multiple sclerosis drugs market. It is projected to grow at a CAGR of 6.9% during the forecast period. The global market is projected to grow from USD 22.32 billion in 2022 to USD 31.90 billion by 2030.

Multiple sclerosis is defined as an immunological disorder, which hinders the normal functioning of the brain. Treatment methods, such as drugs, therapies, and exercise, help to control the disease progression. The increasing prevalence of multiple sclerosis along with increasing government initiatives to reduce the cost of MS treatment through drugs has been fueling the Asia Pacific multiple sclerosis drugs market growth.

  • For instance, in May 2017, the All India Institute of Medical Sciences (AIIMS) urged the Prime Minister of India and the Indian Council of Medical Research (ICMR) to make it mandatory for doctors in India to prescribe the much cheaper and effective Azathioprine (immunomodulators) to treat multiple sclerosis, than other U.S. FDA approved drugs in the Asia Pacific multiple sclerosis drugs market. Furthermore, studies have shown Azathioprine to be effective in treating multiple sclerosis. Hence, such initiatives will strongly propel segmental growth.

Our report on the Asia Pacific market covers the following countries/regions – China, India, Japan, Australia, South East Asia, and the rest of Asia Pacific.


Increasing Clinical Studies by Market Players to Fuel the Market Growth

Awareness regarding the multiple sclerosis drugs for the effective treatment has increased recently in the Asia Pacific countries. In order to fuel this demand, the pharmaceutical companies increased their development of multiple sclerosis drugs.

  • For instance, in October 2021, Merck KGaA announced the enrollment of Evobrutinib for phase 3 clinical trials.

The launch of these drugs in Asia Pacific countries will fuel the Asia Pacific multiple sclerosis drugs market growth in the region.


New Product Approvals to Fuel Market Growth in the Region

Pharmaceutical companies have increased their focus on the development and commercialization of MS drugs in Asia Pacific countries.

  • In August 2018, Sanofi announced that its business segment Sanofi Genzyme launched its multiple sclerosis treatment drug Aubagio in India.

A rise in such product approvals is expected to fuel market growth in the forecast period.


Request a Free sample to learn more about this report.

Lack of Awareness and Limitations Associated with Disease Diagnosis Tend to Limit the Market Growth

Multiple sclerosis occurs when the immune system damages the protective nerve covering. The symptoms include disruption in the normal functioning of the body. These symptoms sometimes go undiagnosed.

Moreover, sometimes people are not well aware about the symptoms and the disease.

The key examinations include MRI and the lumbar puncture for cerebrospinal fluid. In the emerging countries, owing to the lack of healthcare infrastructure as well as the skilled neurologists, there is a gap between the required diagnostic assistance and their supply.

These factors are expected to affect the growth of the market during the forecast period.


Biogen, Novartis AG, and F. Hoffman-La Roche Ltd. are the major players and accounted for significant portion of the Asia Pacific multiple sclerosis drugs market share. The dominance of these players in the market is due to the strong sales of these companies’ MS drugs portfolio. 

Other players are Teva Pharmaceutical Industries Ltd., Pfizer Inc., and Bristol-Myers Squibb Company. These companies have been focusing on strategic initiatives such as mergers and acquisitions to strengthen their positions in the market.


  • Biogen (U.S.)

  • Pfizer Inc. (U.S.)

  • F. Hoffmann-La Roche Ltd. (Switzerland)

  • Novartis AG (Switzerland)

  • Merck & Co., Inc. (U.S.)

  • Sanofi (France)

  • Teva Pharmaceutical Industries Ltd. (Israel)

  • Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation) (New Jersey)

  • Bristol-Myers Squibb Company (U.S.)


  • October 2020: Janssen Pharmaceuticals, Inc. announced the acquisition of Momenta Pharmaceuticals, Inc. The company is involved in R&D of novel therapies for immune-mediated diseases.

  • May 2019: Teva Pharmaceutical Industries Ltd. announced the launch of its product Copaxone for the treatment of relapsing MS.

  • May 2019: Merck KGaA joined the global Multiple Sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple Sclerosis International Federation (MSIF) to raise awareness of the people worldwide living with this challenging disease.


To gain extensive insights into the market, Request for Customization

The research report provides qualitative and quantitative insights on the market and a detailed analysis of the Asia Pacific market size & growth rate for all possible segments in the market. Along with the Middle East & Africa market forecast, the report provides an elaborative analysis of the market dynamics and competitive landscape. Various key insights presented in the report are overview of the prevalence of the disease, pipeline analysis, new product launches, key industry developments – mergers, acquisitions & partnerships and, the impact of COVID-19 pandemic on the market.

Report Scope & Segmentation



Study Period


Base Year


Estimated Year


Forecast Period


Historical Period


Growth Rate

CAGR of 6.9% from 2023 to 2030


Value (USD Billion)


Drug Class; Route of Administration; Distribution Channel; and Country/Sub-Region

By Drug Class

  • Immunomodulators

  • Immunosuppressants

  • Interferons

  • Others

By Route of Administration

  • Oral

  • Injection

    • Intramuscular

    • Subcutaneous

    • Intravenous

By Distribution Channel

  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy

By Country/Sub-Region

  • China

  • India

  • Japan

  • Australia

  • South East Asia

  • Rest of Asia Pacific

Frequently Asked Questions

Growing at a CAGR of 6.9%, the market will exhibit steady growth in the forecast period (2023-2030).

Increasing prevalence of multiple sclerosis and strong presence of pipeline drugs have been fueling the market growth.

Biogen, F. Hoffman-La Roche Ltd., Novartis AG, and Sanofi are the major market players in the Asia Pacific market.

Japan dominated the market in 2022.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
  • Aug, 2023
  • 2022
  • 2019-2021
  • 109


  • $3850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- UGlobal hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.